Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Nyxoah ( (NYXH) ).
On December 2, 2025, Nyxoah SA announced it received transparency notifications indicating changes in shareholding by Robert Taub and BMI Estate. As of December 1, 2025, Robert Taub and BMI Estate hold 10.14% of Nyxoah’s voting rights, surpassing the 10% threshold. This change in shareholding reflects a strategic adjustment in the control of Nyxoah’s voting rights, potentially impacting the company’s governance and stakeholder dynamics.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR10.50 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a company operating in the medical technology industry, focusing on innovative solutions for sleep apnea treatment. The company’s primary product is a neurostimulation therapy designed to treat Obstructive Sleep Apnea (OSA), targeting a significant market of patients who suffer from this condition.
Average Trading Volume: 94,271
Current Market Cap: €177.5M
For detailed information about NYXH stock, go to TipRanks’ Stock Analysis page.